Elite Pharmaceuticals Inc (ELTP)

[lasers]

Switching a patient from Oxycontin® Oxycodone to ELI200® Morphine will be very much patient specific. Depending on the patient's age, gender, and years on opioids, each will be determined exactly as to what Morphine dose will be required to produce the same relief comfort from their pain.

The nomograph's caculation of 80mg Oxycodone PO requiring 60mg Morphine PO is simply a weighted average of the data used to develop the conversion parameters.

https://clincalc.com/Opioids/

Some 80mg Oxycontin® patients will require more than 60mg ELI200® and some less depending on their body's reaction to the synthetic opioid Oxycodone vs their body's reaction to natural opioid Morphine.

Bottom line and most important to $ELTP will be that the $4/$5 to $14/$15 revenue per pill avg of ELI200 consumed, enormous wealth will flow to $ELTP treasury. From $millions initially to potentially $billions as market penetration develops.

Any wonder then why $ELTP are installing now their new 5x capacity Fluid Bed Dryer and hired their three new specialists

Northvale, New Jersey, Friday, October 24, 2014: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.

Yes indeed $ELTP is heading rapidly towards major Pharma status with a +$billion Capital Market structure.